Concurrent Nab-paclitaxel with Intensity-modulated Radiation Therapy in Patients with Stage III-IVa Nasopharyngeal Carcinoma

This study is testing whether adding nab-paclitaxel (a chemotherapy drug delivered in a special nanoparticle form) to standard radiation therapy improves outcomes for patients with Stage III–IVa nasopharyngeal carcinoma — a type of head and neck cancer that starts in the back of the nose. The study is looking at whether this combination is safe and more effective than radiation alone or with standard chemotherapy. **You may be eligible if...** - You have been diagnosed with nasopharyngeal carcinoma confirmed by biopsy - Your cancer is Stage III or IVa - You are between 18 and 70 years old - You are in good general health (performance status 0–1) - Your organs can tolerate chemotherapy and radiation **You may NOT be eligible if...** - You have had another cancer in the past 5 years (except certain very early-stage cancers) - You have heart failure, unstable angina, recent heart attack, active serious infections, psychiatric disorders, or major social/family circumstances that prevent participation Talk to your doctor to see if this trial is right for you.